Anti-SARS-CoV-2 immunoglobulin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Anti-SARS-CoV-2 immunoglobulin
DrugBank Accession Number
DB16360
Background

Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG) is obtained from the plasma of patients who recover from COVID-19 and develop neutralizing antibodies.1 Anti-coronavirus immunoglobulin is derived from COVID-19 convalescent plasma(https://go.drugbank.com/drugs/DB15692) but contains more SARS-CoV-2 neutralizing antibodies than found in convalescent plasma as the antibodies are highly purified and concentrated.1,2

Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Polyclonal antibody (pAb)
Protein Chemical Formula
Not Available
Protein Average Weight
Not Available
Sequences
Not Available
Synonyms
  • Anti-Coronavirus immunoglobulin
  • Anti-COVID-19 hyperimmune globulin (human)
  • GC5131
  • hIVIG
  • Human plasma-derived immune-globulin for Coronavirus
  • Hyperimmune immunoglobulin to SARS-CoV-2
  • Immune-globulin for Coronavirus disease (COVID-19)
  • SARS-CoV-2 antibody-based IVIG
  • SARS-CoV-2 immunoglobulin
External IDs
  • Anti-SARS-CoV-2 immunoglobulin

Pharmacology

Indication

Not Available

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
YU7FRC8N2E
CAS number
Not Available

References

General References
  1. ClinicalTrials.gov: IInpatient Treatment With Anti-Coronavirus Immunoglobulin (ITAC) [Link]
  2. European Pharmaceutical Review: Trial testing anti-coronavirus hIVIG plus remdesivir in COVID-19 patients [Link]
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentCoronavirus Disease 2019 (COVID‑19) / COVID / Severe Acute Respiratory Syndrome (SARS)1
3CompletedTreatmentInfluenza A Virus Infection / Influenza Type B1
3RecruitingTreatmentCoronavirus Disease 2019 (COVID‑19) / COVID1
2CompletedTreatmentCoronavirus Disease 2019 (COVID‑19)1
1, 2CompletedTreatmentCoronavirus Disease 2019 (COVID‑19)1
1, 2CompletedTreatmentCoronavirus Disease 2019 (COVID‑19) / Viral Pneumonia1
1, 2Not Yet RecruitingTreatmentCoronavirus Disease 2019 (COVID‑19)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on December 17, 2020 17:42 / Updated on February 13, 2021 10:53